Geron to Discontinue Phase 3 Imetelstat Trial in Myelofibrosis
Geron disclosed in an SEC filing that it will discontinue the Phase 3 IMpactMF trial of imetelstat in myelofibrosis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Geron Discontinues Phase 3 Myelofibrosis Trial
Geron announced a decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in relapsed/refractory myelofibrosis.